Literature DB >> 2527641

One-year follow-up results of the 1985-1986 National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry.

K Detre1, R Holubkov, S Kelsey, M Bourassa, D Williams, D Holmes, G Dorros, D Faxon, R Myler, K Kent.   

Abstract

In 1,801 patients in the 1985-1986 Percutaneous Transluminal Coronary Angioplasty Registry, overall 1-year mortality was 3.2%, the 1-year myocardial infarction rate was 7.2%, and the 1-year coronary artery bypass surgery rate was 13.2%. In the 78% of the cohort with all lesions successfully dilated and without major procedural complications (successful patients), the corresponding rates were 1.9%, 2.6%, and 6.4%. Nearly 20% of all deaths, 40% of all infarctions, and 25% of all bypass operations occurred in the small subset of patients (6.8%) who sustained periprocedural occlusion. Event rates were higher in patients with multivessel disease than in those with one-vessel disease. At 1 year, angina-free status was reported by approximately three fourths of all surviving patients, regardless of initial success. However, compared with successful patients, unsuccessful patients underwent intervening bypass surgery (42% vs. 6%) to achieve asymptomatic status more frequently. Comparison of the 1-year event rates in the 1985-1986 registry with those in the 1977-1981 registry indicated reductions in all major untoward events. These reductions became apparent after controlling for the more extensive disease of the 1985-1986 registry patients. In contrast, use of repeat angioplasty has increased by 50%. We conclude that the improved initial results reported in the 1985-1986 registry cohort were maintained at 1-year follow-up.

Entities:  

Mesh:

Year:  1989        PMID: 2527641     DOI: 10.1161/01.cir.80.3.421

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Nuclear cardiology: the interventionalists' perspective.

Authors:  H L Haronian; H S Cabin
Journal:  J Nucl Cardiol       Date:  1994 Jul-Aug       Impact factor: 5.952

2.  Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure.

Authors:  L Bonneux; J J Barendregt; K Meeter; G J Bonsel; P J van der Maas
Journal:  Am J Public Health       Date:  1994-01       Impact factor: 9.308

3.  The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.

Authors:  M Texter; R S Lees; B Pitt; R E Dinsmore; A C Uprichard
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

4.  Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries.

Authors:  Lakshmi Venkitachalam; Kevin E Kip; Faith Selzer; Robert L Wilensky; James Slater; Suresh R Mulukutla; Oscar C Marroquin; Peter C Block; David O Williams; Sheryl F Kelsey
Journal:  Circ Cardiovasc Interv       Date:  2008-12-15       Impact factor: 6.546

5.  Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry.

Authors:  Lakshmi Venkitachalam; Kevin E Kip; Suresh R Mulukutla; Faith Selzer; Warren Laskey; James Slater; Howard A Cohen; Robert L Wilensky; David O Williams; Oscar C Marroquin; Kim Sutton-Tyrrell; Clareann H Bunker; Sheryl F Kelsey
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-10-13

Review 6.  Role of percutaneous transluminal coronary angioplasty in the treatment of patients with multivessel coronary artery disease: a review.

Authors:  J J Glazier; J Piessens
Journal:  J R Soc Med       Date:  1991-04       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.